The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lupus content recommended for you
During the 14th European Lupus Meeting 2024, the Lupus Hub was pleased to speak with Jill Buyon, New York University, New York, US. We asked, What are some of the key updates in the management of lupus during pregnancy?
What are some of the key updates in the management of lupus during pregnancy?
Firstly, Jill Buyon discusses two ongoing studies investigating pregnancy outcomes in women with anti-Ro antibodies or antiphospholipid antibodies. The first study, Surveillance and Treatment tO Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ, NCT04474223), focuses on monitoring maternal anti-Ro antibodies and using fetal heart rate monitoring to detect advanced disease, thereby offering possibilities for early intervention and improved monitoring strategies. The second study, IMProve Pregnancy in APS With Certolizumab Therapy (IMPACT, NCT03152058), aims to evaluate the efficacy of certolizumab in pregnant women with antiphospholipid syndrome.
